Afferent Pharmaceuticals
Merck aspires to be the premier research-intensive biopharmaceutical company, dedicated to using leading-edge science to develop medicines and vaccines that help fight serious health concerns worldwide. With over 130 years of history, Merck focuses on innovation, scientific excellence, and responsible operation to improve lives globally. The company emphasizes diversity, inclusion, and a culture of ethics and integrity, aiming to deliver transformative health solutions in human and animal health.
Industries
Nr. of Employees
small (1-50)
Afferent Pharmaceuticals
126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065 USA
Patents
Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough
US-11260056-B2
View Details
Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough
US-11260056-B2
View DetailsProducts
Human vaccines
Preventive vaccines across multiple indications supplied for global public health use.
Small-molecule therapeutics
Oral and injectable small-molecule drugs across therapeutic areas including oncology, infectious disease and cardio‑metabolic disorders.
Biologic therapies and monoclonal antibodies
Biologic medicines and monoclonal antibody products developed for oncology, infectious disease and other indications.
Veterinary pharmaceuticals, vaccines and animal health solutions
Veterinary medicines and vaccines plus health management solutions for livestock and companion animals, including connected systems for identification and monitoring.
Human vaccines
Preventive vaccines across multiple indications supplied for global public health use.
Small-molecule therapeutics
Oral and injectable small-molecule drugs across therapeutic areas including oncology, infectious disease and cardio‑metabolic disorders.
Biologic therapies and monoclonal antibodies
Biologic medicines and monoclonal antibody products developed for oncology, infectious disease and other indications.
Veterinary pharmaceuticals, vaccines and animal health solutions
Veterinary medicines and vaccines plus health management solutions for livestock and companion animals, including connected systems for identification and monitoring.
Services
Protocol development, trial recruitment, global trial conduct and resources to help patients find and join studies.
Programs to support patients with financial assistance options and resources for care navigation.
24/7 telephone and digital intake for adverse events and product quality complaints with escalation and investigation processes.
Services to evaluate, structure and execute collaborations, licensing agreements and partnerships to advance external and internal research programs.
Structured postdoctoral placements providing research experience within industry R&D laboratories.
Mechanism for external security researchers to report potential vulnerabilities and coordinate remediation with internal security teams.
Protocol development, trial recruitment, global trial conduct and resources to help patients find and join studies.
Programs to support patients with financial assistance options and resources for care navigation.
24/7 telephone and digital intake for adverse events and product quality complaints with escalation and investigation processes.
Services to evaluate, structure and execute collaborations, licensing agreements and partnerships to advance external and internal research programs.
Structured postdoctoral placements providing research experience within industry R&D laboratories.
Mechanism for external security researchers to report potential vulnerabilities and coordinate remediation with internal security teams.
Expertise Areas
- Clinical trial management
- Pharmacovigilance and safety reporting
- Vaccine development
- Biologics and vaccine manufacturing
Key Technologies
- Machine learning and generative AI
- Real‑world evidence analytics
- Antibody‑drug conjugate platforms
- Vaccine development platforms
News & Updates
The FDA has granted priority review for Merck's WINREVAIR™ (sotatercept-csrk) to update its label based on results from the ZENITH trial.
Merck announced it will hold a conference call to discuss its Q2 2025 sales and earnings on July 29.
The CDC's Advisory Committee on Immunization Practices (ACIP) recommended Merck's ENFLONSIA™ (clesrovimab-cfor) for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants.
Merck announced an upcoming investor event to showcase its research pipeline for HIV treatment and prevention.
Merck announced that its Phase 3 Hyperion study of WINREVAIR™ (sotatercept-csrk) met its primary endpoint in recently diagnosed adults with pulmonary arterial hypertension.
Merck announced the initiation of its Phase 3 IDeate-Prostate01 trial of the drug candidate, targeting metastatic castration-resistant prostate cancer.
The FDA has granted priority review for Merck's WINREVAIR™ (sotatercept-csrk) to update its label based on results from the ZENITH trial.
Merck announced it will hold a conference call to discuss its Q2 2025 sales and earnings on July 29.
The CDC's Advisory Committee on Immunization Practices (ACIP) recommended Merck's ENFLONSIA™ (clesrovimab-cfor) for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants.
Merck announced an upcoming investor event to showcase its research pipeline for HIV treatment and prevention.
Merck announced that its Phase 3 Hyperion study of WINREVAIR™ (sotatercept-csrk) met its primary endpoint in recently diagnosed adults with pulmonary arterial hypertension.
Merck announced the initiation of its Phase 3 IDeate-Prostate01 trial of the drug candidate, targeting metastatic castration-resistant prostate cancer.